title: Issues that led to the withdrawal of cerivastatin.
authors.affiliation: Global Strategic Regulatory Development, Merck and Company, 126 Lincoln Avenue, Rahway NJ, 07065-0900, USA. donald_black@merck.com
authors.forename: Donald M
authors.initials: DM
authors.lastname: Black
mesh_terms: D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000009:adverse effects*; D009135:Muscular Diseases / Q000139:chemically induced*; D011358:Product Surveillance, Postmarketing; D011725:Pyridines / Q000009:adverse effects*; D014481:United States
chemical_list: D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D011725:Pyridines; C086276:cerivastatin